PPARG and early-onset autosomal dominant Alzheimer disease: Various studies have demonstrated that activation of PPAR‐γ presents a promising therapeutic target for the management of traumatic brain injury (TBI) [20], ischemic brain injury [19], Parkinson's disease [43], and Alzheimer's disease [44] in animal models.